Back to results
US 5,633,426 AGranted
In vivo use of human bone marrow for investigation and production
AssigneeSystemix, Inc.
InventorsReiko Namikawa, Seishi Kyoizumi, Joseph M. McCune, Hideto Kaneshima
Life of this patent
Estimating the term…
Abstract
Chimeric immunocompromised hosts are provided, comprising human bone marrow of at least 4 weeks from the time of implantation. The bone marrow is found to assume the normal population of bone marrow except for erythrocytes. The bone marrow may be used to study the effect of various agents on the proliferation and differentiation of hematopoietic cells.
Claims20
A chimeric immunocompromised mouse, said mouse comprising:
- an immunodeficient mouse host lacking functional syngeneic lymphocytes as a result of a genetic defect in immunoglobulin and T cell receptor gene rearrangement;
- and
- vascularized normal human fetal bone marrow and human fetal stroma resulting from the implantation of a human fetal bone or fragment thereof grown in said immunodeficient mouse host for a period of at least four weeks.
A chimeric immunocompromised mouse, said mouse comprising:
- a scid/scid mouse host;
- and
- vascularized normal human fetal bone marrow and human fetal stroma resulting from the implantation of a human fetal bone or fragment thereof grown in said scid/scid mouse host for a period of at least four weeks.
Dependencies are inferred from the claim text.